These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 15297275)

  • 21. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.
    Chmiel C; Speich R; Hofer M; Michel D; Mertens T; Weder W; Boehler A
    Clin Infect Dis; 2008 Mar; 46(6):831-9. PubMed ID: 18269330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of prophylactic use of sirolimus on bronchiolitis obliterans syndrome development in lung transplant recipients.
    Sacher VY; Fertel D; Srivastava K; Panos A; Nguyen D; Baxter T; Shafazand S; Pham SM
    Ann Thorac Surg; 2014 Jan; 97(1):268-74. PubMed ID: 24119986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients.
    Danziger-Isakov LA; DelaMorena M; Hayashi RJ; Sweet S; Mendeloff E; Schootman M; Huddleston CB; DeBaun MR
    Transplantation; 2003 May; 75(9):1538-43. PubMed ID: 12792511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1.
    Burton CM; Iversen M; Carlsen J; Mortensen J; Andersen CB; Steinbrüchel D; Scheike T
    J Heart Lung Transplant; 2009 Sep; 28(9):888-93. PubMed ID: 19716040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lung transplantation for cystic fibrosis: 6-year follow-up.
    Quattrucci S; Rolla M; Cimino G; Bertasi S; Cingolani S; Scalercio F; Venuta F; Midulla F
    J Cyst Fibros; 2005 May; 4(2):107-14. PubMed ID: 15914093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Innate immunity influences long-term outcomes after human lung transplant.
    Palmer SM; Burch LH; Trindade AJ; Davis RD; Herczyk WF; Reinsmoen NL; Schwartz DA
    Am J Respir Crit Care Med; 2005 Apr; 171(7):780-5. PubMed ID: 15640363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.
    Soghikian MV; Valentine VG; Berry GJ; Patel HR; Robbins RC; Theodore J
    J Heart Lung Transplant; 1996 Sep; 15(9):881-7. PubMed ID: 8889983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden.
    Johanssson I; Mårtensson G; Andersson R
    Scand J Infect Dis; 2010; 42(2):129-36. PubMed ID: 20082575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation.
    Glanville AR; Aboyoun CL; Havryk A; Plit M; Rainer S; Malouf MA
    Am J Respir Crit Care Med; 2008 May; 177(9):1033-40. PubMed ID: 18263803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of donor-recipient cytomegalovirus serology on adult liver transplantation: a single center experience.
    Tryphonopoulos P; Weppler D; Morris MI; Russo C; Nishida S; Levi DM; Moon J; Tekin A; Selvaggi G; Island E; Arosemena L; Ruiz P; Tzakis AG
    Transplantation; 2011 Nov; 92(9):1051-7. PubMed ID: 21876474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Probabilistic modeling of cytomegalovirus infection under consensus clinical management guidelines.
    Dmitrienko S; Balshaw R; Machnicki G; Shapiro RJ; Keown PA
    Transplantation; 2009 Feb; 87(4):570-7. PubMed ID: 19307796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postlung transplant survival is equivalent regardless of cytomegalovirus match status.
    Russo MJ; Sternberg DI; Hong KN; Sorabella RA; Moskowitz AJ; Gelijns AC; Wilt JR; D'Ovidio F; Kawut SM; Arcasoy SM; Sonett JR
    Ann Thorac Surg; 2007 Oct; 84(4):1129-34; discussion 1134-5. PubMed ID: 17888958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation.
    Treede H; Glanville AR; Klepetko W; Aboyoun C; Vettorazzi E; Lama R; Bravo C; Knoop C; Aubert JD; Reichenspurner H;
    J Heart Lung Transplant; 2012 Aug; 31(8):797-804. PubMed ID: 22554673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The killer immunoglobulin-like receptor (KIR) group A haplotype is associated with bronchiolitis obliterans syndrome after lung transplantation.
    Kwakkel-van Erp JM; van de Graaf EA; Paantjens AW; van Ginkel WG; Schellekens J; van Kessel DA; van den Bosch JM; Otten HG
    J Heart Lung Transplant; 2008 Sep; 27(9):995-1001. PubMed ID: 18765192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surveillance bronchoscopy in lung transplant recipients: risk versus benefit.
    McWilliams TJ; Williams TJ; Whitford HM; Snell GI
    J Heart Lung Transplant; 2008 Nov; 27(11):1203-9. PubMed ID: 18971092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation.
    Kroshus TJ; Kshettry VR; Savik K; John R; Hertz MI; Bolman RM
    J Thorac Cardiovasc Surg; 1997 Aug; 114(2):195-202. PubMed ID: 9270635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of CMV pneumonia in the development of obliterative bronchiolitis in heart-lung and double-lung transplant recipients.
    Cerrina J; Le Roy Ladurie F; Herve PH; Parquin F; Harari S; Chapelier A; Simoneau G; Vouhe P; Dartevelle PH
    Transpl Int; 1992; 5 Suppl 1():S242-5. PubMed ID: 14621790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology.
    Husain S; Singh N
    Semin Respir Infect; 2002 Dec; 17(4):310-4. PubMed ID: 12497548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
    Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients.
    Bhorade SM; Lurain NS; Jordan A; Leischner J; Villanueva J; Durazo R; Creech S; Vigneswaran WT; Garrity ER
    J Heart Lung Transplant; 2002 Dec; 21(12):1274-82. PubMed ID: 12490272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.